包含选择性雌激素受体调节剂(SERM)的阴道递送系统及其用途

本发明提供药物组合物,其包含一种或多种选择性雌激素受体调节剂(SERM,例如,拉索昔芬)和四种或更多种药学上可接受的赋形剂。该药物组合物可以在阴道液体中形成纳米液滴(例如,通过自纳米乳化)且将一种或多种SERM递送至雌性受试者阴道。该药物组合物可用于治疗或预防雌性受试者的外阴阴道萎缩、性交困难、性功能障碍、骨质疏松或乳腺癌。 The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s),...

Full description

Saved in:
Bibliographic Details
Format Patent
LanguageChinese
Published 22.11.2022
Subjects
Online AccessGet full text

Cover

More Information
Summary:本发明提供药物组合物,其包含一种或多种选择性雌激素受体调节剂(SERM,例如,拉索昔芬)和四种或更多种药学上可接受的赋形剂。该药物组合物可以在阴道液体中形成纳米液滴(例如,通过自纳米乳化)且将一种或多种SERM递送至雌性受试者阴道。该药物组合物可用于治疗或预防雌性受试者的外阴阴道萎缩、性交困难、性功能障碍、骨质疏松或乳腺癌。 The present disclosure provides pharmaceutical compositions that include one or more selective estrogen receptor modulator(s) (SERM(s), e.g., Lasofoxifene) and four or more pharmaceutically acceptable excipients. The pharmaceutical compositions may be able to form nanodroplets (e.g., by self-nanoemulsifying) in vaginal fluid and to deliver the one or more SERM(s) to the vagina of a female subject. The pharmaceutical compositions may be useful in treating or preventing vulvovaginal atrophy, dyspareunia, sexual dysfunction, osteoporosis, or breast cancer in a female subject.
Bibliography:Application Number: CN20178044937